Drug Profile
Research programme: protein kinase inhibitors - AbbVie
Alternative Names: A 1467729; A-443654; A-947864Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Heterocyclic bicyclo compounds; Indazoles; Pyridines; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Checkpoint kinase 1 inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase inhibitors; Epidermal growth factor receptor antagonists; Insulin-like growth factor-I receptor antagonists; Janus kinase-2 inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 03 Dec 2016 Pharmacodynamics data from preclinical studies in Mantle cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie